How qualified participant referrals solve the site recruitment problem

Recruitment continues to be the single largest source of delay in clinical trials. At the site level, that pressure shows up as too few eligible candidates moving through the screening process, coordinator time consumed by inquiries that fail to qualify, and enrollment timelines that stretch past sponsor expectations. The structural fix is not more inquiries. It is better ones. Qualified participant referrals change what arrives at the site and, with that, what the site can actually convert.

The recruitment problem at the site level

Patient recruitment accounts for roughly a third of total clinical trial costs and is the most common reason studies miss their timelines. From the site perspective, the problem rarely looks like a single failure point. It looks like a series of small inefficiencies that compound.

Inquiries arrive through fragmented channels: advocacy outreach, search advertising, registries, direct walk-ins, and partner platforms. Each channel applies different filters before the referral reaches the coordinator's inbox. Many apply almost none. The result is a coordinator who spends hours on outreach calls only to confirm that the candidate is not eligible for any active protocol at the site.

Screen failure rates compound the same problem at the next stage. Industry literature has placed the proportion of referrals that fail formal screening at roughly seven out of ten. That number reflects every step in the chain: how well the candidate was matched to the protocol, how accurate the pre-screening data was, how thorough the protocol's eligibility criteria are, and how well the site was able to confirm or rule out borderline cases.

For a small site running multiple protocols at once, the practical impact is severe. A team of one or two coordinators cannot absorb hundreds of unqualified inquiries while still running visits, managing source documents, and supporting active participants. Recruitment partners exist to remove that load, but only when their referrals carry enough qualifying information to be worth the coordinator's time. For a deeper look at the operational pressure most sites are under, see The Recruitment Struggle Is Real: What Today's Sites Need to Compete.

What a qualified participant referral actually means

The word "referral" covers a very wide range of inputs. At one end, it can mean nothing more than a name and a phone number generated by a digital advertisement. At the other end, it can mean a candidate who has already worked through structured eligibility questions, answered them honestly, and been reviewed by a clinician before the referral is forwarded to the site.

Pre-screening sits between these two ends. It is the layer of filtering that happens before the candidate is sent to the site. A qualified participant referral typically arrives with key facts already collected: the candidate's age, the relevant condition, current medications, location relative to the site, prior treatment history or trial participation, and answers to the most common inclusion and exclusion questions that the candidate can self-report.

That is not the same as full eligibility confirmation. Protocol-specific assessments can only be performed at the site once the trial has Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approval and the candidate has provided informed consent. International Council for Harmonisation Good Clinical Practice (ICH-GCP) guidelines are explicit on this point. Laboratory tests, imaging, clinician-administered scales, and washout requirements that must be verified against medical records all belong to the site's screening visit, not to upstream pre-screening.

What a qualified participant referral does is concentrate the site's screening effort on what actually requires the site to do it. The coordinator is no longer asking the candidate to repeat basic information already collected. The screening visit becomes a confirmation step rather than a first filter. The technology and clinical judgment behind smarter pre-screening is covered in Pre-Screening Smarter: How Technology Reduces Screen Failures at Sites.

How qualified referrals change the math for sites

The shift from unfiltered referrals to qualified ones changes the unit economics of site operations. Three effects are most visible.

First, screen failure rates fall. When candidates have been filtered against the protocol's key eligibility criteria upstream, a higher proportion of those who reach the site clear the formal screening visit. Coordinator time spent per enrollment drops as a direct consequence, freeing capacity for retention, source document management, and concurrent protocols.

Second, candidate engagement holds. Industry tracking data suggests that candidates remain engaged with a trial opportunity for several days after the initial referral without significant drop-off. The candidate's confidence in the process, however, is shaped by what happens at the first site contact. A candidate who is asked to re-confirm basic information already shared with the recruitment partner loses confidence in the site team. A candidate whose first conversation moves directly to scheduling and protocol-specific questions is far more likely to complete the screening visit.

Third, capacity planning becomes more predictable. With a recruitment partner calibrating volume to site capacity, the coordinator is not flooded one week and starved the next. Predictable inflow allows the site to schedule screening visits, lab draws, and follow-up calls in a way that matches the rest of the clinic's workload. For a closer look at how sites can reduce screen failures end to end, see Reducing Screen Failures in Clinical Trials: How Sites Can Improve Eligibility Matching.

What sites should expect from a recruitment partner

Sites should evaluate a recruitment partner on more than referral volume. Five characteristics distinguish a partner whose referrals are worth the coordinator's time.

Documented pre-screening criteria. The partner can show, in writing, which inclusion and exclusion items they screen on before referring a candidate. The site should not have to guess what the candidate has and has not been asked.

Pre-screening data delivered with the referral. The candidate's answers to pre-screening questions arrive at the site with the referral itself, in a format the coordinator can read without logging into a separate system. The candidate is not asked to repeat what they have already answered.

A defined feedback loop. When a referral fails screening at the site, the site can record the reason and that reason flows back to the partner. The partner then adjusts upstream filtering or messaging to reduce similar failures in future cohorts.

Real-time status visibility. The site, the partner, and the sponsor can see where each referral sits in the pipeline at any moment. Weekly status emails and back-and-forth on referral counts are replaced by a shared view of the funnel.

Volume calibrated to site capacity. The partner does not flood the site with referrals during low-staffing weeks. Volume scales with what the site can actually action. A site that walks into a partnership without these expectations set in advance is more likely to end up with the worst pattern in patient recruitment: high volume, low conversion, and a coordinator who has lost faith in the partner.

Where site responsibility still begins and ends

A recruitment partner can do a great deal of work before the candidate reaches the site. None of that work removes the site's regulatory accountability for what happens once the candidate is on protocol.

ICH-GCP is unambiguous on the investigator's responsibilities. The principal investigator is required to conduct the study in accordance with the protocol, to personally conduct or supervise study-related procedures, to ensure that study-specific screening assessments are not performed before IRB or IEC approval, and to obtain valid informed consent from each participant before any protocol-mandated procedure begins. The investigator is also responsible for maintaining case histories for every person screened, including those who fail screening, with the reasons documented in source documents.

What this means in practice is that the qualified referral starts a process that the site, not the partner, completes. The site verifies the pre-screening data against the candidate's medical records during the formal screening visit. The site administers any protocol-specific tests required for eligibility. The site reviews the informed consent form with the candidate, answers questions, and obtains valid consent. The site makes the final enrollment decision.

The recruitment partner's job is to put the site in a position to do that work efficiently. The site's job is to do it well. Compliance practices that support that work are covered in Clinical Trial Compliance: Essential Practices Every Site Must Follow.

How DecenTrialz delivers qualified participant referrals to research sites

DecenTrialz is built around the operational pattern described above. The platform identifies and matches potential participants to active studies using artificial intelligence (AI) for matching against the structured eligibility criteria of each protocol. Candidates who appear to be a fit are routed into a pre-screening workflow that captures the structured questions the protocol requires the candidate to self-report.

A registered nurse on the DecenTrialz team then completes an initial pre-screening review before any referral leaves the platform. That review confirms the candidate's answers are internally consistent, flags anything that needs follow-up, and ensures the referral that reaches the site carries reliable pre-screening data rather than a name and a phone number.

The referral arrives at the site with the pre-screening data already attached, formatted so that the coordinator can move directly to scheduling rather than re-asking the candidate. Final eligibility, enrollment, and informed consent are always handled by the study team responsible for the trial. The site retains full ownership of formal screening, protocol-specific assessments, the informed consent conversation, and the enrollment decision.

Real-time recruitment dashboards give the site team, the sponsor, and the Contract Research Organization (CRO) visibility into where each referral sits in the funnel. Sites can see referral volume, screen failure reasons, and conversion at a glance. Sponsors and CROs see the same data without asking the site to compile a report. For a closer look at how site performance shows up in those metrics, see Building Sponsor Trust: Metrics That Show Site Performance.

Next steps for research sites

Sites do not need more referrals. They need referrals that are worth the coordinator's time, supported by a partner that respects the site's regulatory accountability and operational capacity. Qualified participant referrals make that possible.

For research sites interested in working with DecenTrialz as a recruitment partner, the next step is a conversation about active studies, site capacity, and how the platform fits into existing site workflows. Visit decentrialz.com to start that conversation.